If your child has been diagnosed with myopia and the prescription has been creeping higher at every annual exam, you've likely started researching what can be done to slow it down. Low-dose atropine is one of the options you'll encounter — and it's one of the most extensively researched myopia control interventions available. At Harnos Optometry in New Paltz, NY, atropine is an important tool in our myopia management program, and here's what you need to know about it.
What Is Atropine and How Does It Work for Myopia?
Atropine is an anticholinergic medication that has been used in eye care for over a century — originally at full strength (1%) to dilate pupils and temporarily paralyze the focusing muscle. Decades ago, researchers noticed that full-strength atropine dramatically slowed myopia progression in children, but the side effects — blurry near vision, extreme light sensitivity, and the need for bifocals — made it impractical for daily use.
The breakthrough came when researchers began testing much lower concentrations. Studies with 0.05% and 0.025% atropine — concentrations 20–40 times lower than the original — found that they retained a substantial portion of the myopia control effect with minimal side effects. The ATOM2 and LAMP studies, among others, established low-dose atropine as a genuinely effective and safe myopia control tool.
The exact mechanism isn't fully understood, but it appears that atropine's myopia control effect isn't primarily through the focusing muscle. Rather, it's thought to act directly on retinal receptors that signal the eye to elongate — essentially reducing the biological drive for axial growth.
What to Expect With Atropine Treatment
Low-dose atropine is administered as a nightly eye drop — one drop in each eye before bed. At the concentrations we use (typically 0.05% or lower), most children experience minimal to no side effects. Some may notice very slight pupil dilation or very mild sensitivity to bright light, but this is far less pronounced than with higher concentrations.
Clinical results vary, but on average, low-dose atropine reduces myopia progression by approximately 50–60% compared to no treatment. It can be used as a standalone treatment or combined with optical interventions like Ortho-K or peripheral defocus lenses for enhanced effect — a strategy we use for children at higher risk of significant progression.
Is Atropine Right for My Child?
Low-dose atropine is generally appropriate for myopic children aged 5–18 whose prescriptions are progressing. It requires a prescription from an optometrist and periodic monitoring to assess effectiveness and adjust concentration if needed. We typically recommend annual axial length measurements (a non-invasive measure of eye length) to objectively track whether the treatment is working.
To discuss whether low-dose atropine or another myopia control approach is right for your child, schedule a myopia management consultation at Harnos Optometry in New Paltz — call or text us at (845) 255-4696.